Filter Results
:
(231)
Show Results For
-
All HBS Web
(498)
- Faculty Publications (231)
Show Results For
-
All HBS Web
(498)
- Faculty Publications (231)
- 2020
- Book
Work, Mate, Marry, Love: How Machines Shape Our Human Destiny
By: Debora L. Spar
Covering a time frame that ranges from 8000 BC to the present, and drawing upon both Marxist and feminist theories, the book argues that nearly all the decisions we make in our most intimate lives—whom to marry, how to have children, how to have sex, how to think about...
View Details
Keywords:
Innovation;
Family;
Women;
Reproduction;
Artificial Intelligence;
Robots;
Gender;
Demography;
History;
Innovation and Invention;
Relationships;
Society;
Information Technology;
AI and Machine Learning;
Biotechnology Industry;
Biotechnology Industry;
Biotechnology Industry;
Biotechnology Industry;
Biotechnology Industry;
Biotechnology Industry;
Africa;
Asia;
Europe;
Latin America;
North and Central America
Spar, Debora L. Work, Mate, Marry, Love: How Machines Shape Our Human Destiny. New York: Farrar, Straus and Giroux, 2020.
- June 2020
- Case
Breakthroughs at Blueprint Medicines
By: Richard G. Hamermesh, Kathy Giusti and Susie L. Ma
Precision medicine company Blueprint Medicines was building a successful track record for bringing drug therapies to market 40% faster than average. The company had spent $40 million dollars and two years building a compound library that became its drug development...
View Details
Keywords:
Precision Medicine;
Cancer;
Biotechnology;
Drug Development;
Strategy;
Expansion;
Science;
Genetics;
Information Technology;
Entrepreneurship;
Organizational Culture;
Management;
Growth and Development;
Pharmaceutical Industry;
United States;
Cambridge;
Massachusetts
Hamermesh, Richard G., Kathy Giusti, and Susie L. Ma. "Breakthroughs at Blueprint Medicines." Harvard Business School Case 820-001, June 2020.
- March 2020 (Revised June 2020)
- Case
Social Salary Setting at Spiber
By: Ashley Whillans and John Beshears
Can a “set your own salary” system boost employee happiness and motivation? Spiber made synthetic silk built from proteins mimicking the proteins found in spider silk, the world’s toughest known material by weight. Kazuhide Sekiyama and Junichi Sugahara established...
View Details
Keywords:
Compensation and Benefits;
Motivation and Incentives;
Happiness;
Negotiation Tactics;
Cross-Cultural and Cross-Border Issues;
Biotechnology Industry;
Japan;
United States
Whillans, Ashley, and John Beshears. "Social Salary Setting at Spiber." Harvard Business School Case 920-050, March 2020. (Revised June 2020.)
- November 2019 (Revised April 2020)
- Technical Note
The Life Sciences Revolution: A Technical Primer
By: Gary P. Pisano, William J. Anderson, Amitabh Chandra, Clarissa Ceruti and Stephanie Oestreich
For more than two decades, scientific advances have been driving profound changes in drug discovery and the drug industry itself. This case provides an overview and description of these technical and scientific advances. Written for the nonscientific reader, it may be...
View Details
Keywords:
Science;
Technological Innovation;
Technology;
Pharmaceutical Industry;
Pharmaceutical Industry
Pisano, Gary P., William J. Anderson, Amitabh Chandra, Clarissa Ceruti, and Stephanie Oestreich. "The Life Sciences Revolution: A Technical Primer." Harvard Business School Technical Note 620-054, November 2019. (Revised April 2020.)
- October 2019 (Revised April 2020)
- Background Note
Note on Funding Deep Tech Startups
By: Karim Lakhani, Peter Barrett and Noubar Afeyan
This Background Note provides essential information on funding deep technologies—those technologies that were inherently capital intensive, time consuming, risky, and potentially disruptive. Both dilutive and non-dilutive sources of investment are highlighted, along...
View Details
Keywords:
Entrepreneurship;
Energy;
Venture Capital;
Corporate Finance;
Initial Public Offering;
Investment;
Health Testing and Trials;
Innovation and Invention;
Technological Innovation;
Intellectual Property;
Product Design;
Product Development;
Information Technology;
Research and Development;
Risk and Uncertainty;
Technology Industry;
Technology Industry;
United States;
North America;
Europe;
Asia
Lakhani, Karim, Peter Barrett, and Noubar Afeyan. "Note on Funding Deep Tech Startups." Harvard Business School Background Note 620-029, October 2019. (Revised April 2020.)
- September 2019 (Revised August 2020)
- Case
Engineering an Inclusive Bioeconomy
By: Tarun Khanna, Raffaella Sadun and Susie L. Ma
In 2019, entrepreneur Juan Carlos Castilla-Rubio was developing a project he hoped could generate and share wealth from the natural resources of the Amazon without destroying those resources. His idea, called Earth Bank of Codes (EBC), would create a library of the...
View Details
Keywords:
Decision Making;
Development Economics;
Entrepreneurship;
Innovation and Invention;
Intellectual Property;
Emerging Markets;
Market Design;
Marketplace Matching;
Science;
Genetics;
Natural Environment;
Environmental Sustainability;
Climate Change;
Social Enterprise;
Strategy;
Strategic Planning;
Information Technology;
Ownership;
Social Psychology;
Trust;
Society;
Biotechnology Industry;
South America;
Amazon Basin
Khanna, Tarun, Raffaella Sadun, and Susie L. Ma. "Engineering an Inclusive Bioeconomy." Harvard Business School Case 720-356, September 2019. (Revised August 2020.)
- September 2019
- Case
Nimbus Therapeutics
By: Peter Barrett, Karim Lakhani and Julia Kelley
This case focuses on Nimbus Therapeutics, a biotechnology startup based in Cambridge, Massachusetts, as its leadership team tries to determine the company’s long-term strategy. The startup’s founders structured Nimbus as a limited liability company, which has given it...
View Details
Barrett, Peter, Karim Lakhani, and Julia Kelley. "Nimbus Therapeutics." Harvard Business School Case 620-016, September 2019.
- September 2019
- Case
Bill & Melinda Gates Foundation: Shaping the Vaccine Manufacturing Ecosystem
By: Willy C. Shih
Vaccines for children has been a long-standing focus for the Bill & Melinda Gates Foundation, and its critical role in public health made its production an important economic and political issue. This case describes the Foundation's investment in a breakthrough vaccine...
View Details
Keywords:
Vaccine;
Production;
Supply Chain;
Product;
Biotechnology Industry;
Biotechnology Industry;
Biotechnology Industry;
Belgium
Shih, Willy C. "Bill & Melinda Gates Foundation: Shaping the Vaccine Manufacturing Ecosystem." Harvard Business School Case 620-021, September 2019.
- June 2018
- Teaching Note
Sandra Brown Goes Digital
By: Rosabeth Moss Kanter and Jonathan Cohen
As a middle manager at a biotechnology company, Sandra Brown harnessed digital tools and social media to engage others and build campaigns for change in the company. This Teaching Note presents strategies for teaching the Sandra Brown case series, which follows Brown's...
View Details
- May 2018
- Case
The Multiple Myeloma Research Foundation's Answer Fund
By: Richard G. Hamermesh and Matthew G. Preble
Keywords:
Data Analytics;
Customer Focus and Relationships;
Customer Relationship Management;
Cost vs Benefits;
Investment Return;
Health Care and Treatment;
Innovation Leadership;
Intellectual Property;
Knowledge Sharing;
Knowledge Dissemination;
Leadership;
Leading Change;
Resource Allocation;
Goals and Objectives;
Marketing Communications;
Performance;
Programs;
Projects;
Business and Community Relations;
Business and Stakeholder Relations;
Networks;
Partners and Partnerships;
Research and Development;
Genetics;
Behavior;
Motivation and Incentives;
Social and Collaborative Networks;
Nonprofit Organizations;
Strategy;
Health Industry;
Health Industry;
Health Industry;
United States
- March 2018 (Revised July 2018)
- Case
GreenLight Biosciences: In Search of Impact Investment
By: Michael Chu, Annelena Lobb and Joni Coughlin
Greenlight Biosciences, a biotech company, is in search of impact investment for its next round of financing.
View Details
Keywords:
Impact Investment;
Investment;
Environmental Sustainability;
Financing and Loans;
Biotechnology Industry
Chu, Michael, Annelena Lobb, and Joni Coughlin. "GreenLight Biosciences: In Search of Impact Investment." Harvard Business School Case 318-072, March 2018. (Revised July 2018.)
- March 2018
- Case
Sandra Brown Goes Digital (A): The Promise and Perils of Social Movements in a Healthcare Company
By: Rosabeth Moss Kanter and Jonathan Cohen
As a middle manager at a biotechnology company, Sandra Brown harnessed digital tools and social media to engage others and build campaigns for change in the company. This case follows her career at the company and describes the challenges she faced as a change agent,...
View Details
Keywords:
Digital;
Engagement;
Stakeholder Engagement;
Grassroots Movement;
Organization Change And Adaptation;
Quality;
Health Care;
Health Care Industry;
Career Path;
Leading Change;
Management;
Innovation and Management;
Personal Development and Career;
Organizational Change and Adaptation;
Biotechnology Industry;
Biotechnology Industry
Kanter, Rosabeth Moss, and Jonathan Cohen. "Sandra Brown Goes Digital (A): The Promise and Perils of Social Movements in a Healthcare Company." Harvard Business School Case 318-082, March 2018.
- March 2018 (Revised May 2018)
- Case
Celgene
By: Malcolm Baker and Emily McComb
In February 2011, Adam Koppel, a managing director at Brookside Capital, the public equity arm of Bain Capital, must decide whether to increase or exit the firm’s position in Celgene Corporation. News has emerged that raises potential safety concerns associated with...
View Details
Keywords:
Life Sciences;
Biotechnology;
Public Market Investing;
Celgene;
Revlimid;
Hedge Fund;
Growth Stocks;
Valuation;
Investment;
Decision Choices and Conditions;
Analysis;
Biotechnology Industry
Baker, Malcolm, and Emily McComb. "Celgene." Harvard Business School Case 218-094, March 2018. (Revised May 2018.)
- March 2018 (Revised May 2018)
- Supplement
Celgene (B)
By: Malcolm Baker and Emily McComb
Supplements the (A) case.
View Details
Keywords:
Life Sciences;
Biotechnology;
Public Market Investing;
Celgene;
Revlimid;
Hedge Fund;
Growth Stocks;
Valuation;
Investment;
Decision Choices and Conditions;
Analysis;
Biotechnology Industry
Baker, Malcolm, and Emily McComb. "Celgene (B)." Harvard Business School Supplement 218-099, March 2018. (Revised May 2018.)
- January 2018
- Supplement
BeiGene Supplemental PowerPoint
By: Willy C. Shih and Jimmy Zhang
BeiGene was a biopharmaceutical company founded on exploiting a temporal regulatory policy discontinuity. Because of regulatory challenges in China, most innovative new drugs launched there four to six years after their initial U.S. launches. This gave BeiGene a window...
View Details
- January 2018
- Teaching Note
BeiGene
By: Willy Shih and Jimmy Zhang
Teaching Note for HBS No. 618-033.
View Details
- November 2017
- Case
Passion and Strategy: Novozymes' Embrace of the UN Sustainable Development Goals
By: Andy Zelleke and Emilie Billaud
This case explores the sustainability efforts at Novozymes, the world's largest and oldest producer of industrial enzymes. In 2015, the Danish company became the world’s first company known to have crafted a new corporate strategy based on the United Nations...
View Details
Keywords:
Corporate Governance;
Transformation;
Environmental Sustainability;
Corporate Social Responsibility and Impact;
Mission and Purpose;
Business and Shareholder Relations;
Business and Stakeholder Relations;
Business Strategy;
Organizational Culture;
Organizational Change and Adaptation;
Biotechnology Industry;
Europe;
Denmark
Zelleke, Andy, and Emilie Billaud. "Passion and Strategy: Novozymes' Embrace of the UN Sustainable Development Goals." Harvard Business School Case 318-088, November 2017.
- November 2017
- Case
BeiGene
By: Willy Shih and Jimmy Zhang
BeiGene was a biopharmaceutical company founded on exploiting a temporal regulatory policy discontinuity. Because of regulatory challenges in China, most innovative new drugs launched there four to six years after their initial U.S. launches. This gave BeiGene a window...
View Details
Keywords:
Biotechnology;
Pharmaceutical Company;
Pharmaceuticals;
China;
Regulatory Environment;
Business Strategy;
Business Startups;
Innovation Strategy;
Situation or Environment;
Pharmaceutical Industry;
China
Shih, Willy, and Jimmy Zhang. "BeiGene." Harvard Business School Case 618-033, November 2017.
- November 2016
- Supplement
Alnylam Pharmaceuticals: Building Value from the IP Estate (B)
By: Vicki Sato, Willy Shih and Matt Higgins
The leader of a pioneering biotech company in the siRNA space weighs his options for scaling production capacity in advance of an anticipated commercial launch. Operational complexity and relative merits of in-house manufacturing versus a contractor model are...
View Details
Keywords:
Pharmaceutical Companies;
Pharmaceutical Industry;
Biotech;
Biotechnology;
Operational Complexity;
Strategy;
Manufacturing;
Production;
Strategic Planning;
Intellectual Property;
Biotechnology Industry;
United States
Sato, Vicki, Willy Shih, and Matt Higgins. "Alnylam Pharmaceuticals: Building Value from the IP Estate (B)." Harvard Business School Supplement 617-022, November 2016.
- November 2016
- Case
Anthony Starks at InSiL Therapeutics (A)
By: Gary Pisano and Vicki Sato
When Bruce Wayne hired Anthony Starks, he thought he had hit a home run by getting the most brilliant and passionate scientist-leader in the field to be his CSO. But a few months in, Wayne and Starks begin to clash over crucial forward-looking decisions about the...
View Details
Keywords:
Biotech;
Silicon;
Managing Innovation;
Management Challenges;
Managing People;
Managing Organization;
R&D;
R&D Project Management;
Platform;
Venture Capital;
Drug Discovery;
management;
Biotechnology Industry;
California
Pisano, Gary, and Vicki Sato. "Anthony Starks at InSiL Therapeutics (A)." Harvard Business School Case 617-029, November 2016.